Trial Profile
Activity and Toxicity Profile of Eribulin Mesylate in Pretreated Metastatic Breast Cancer: an Observational Multicentric Retroprospective Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms ReProLine
- 12 Sep 2017 Results (n=446) assessing safety and efficacy, presented at the 42nd European Society for Medical Oncology Congress.
- 12 Sep 2017 Status changed from recruiting to completed, presented at the 42nd European Society for Medical Oncology Congress.
- 23 Mar 2015 New trial record